A first-in-human clinical study of 9MW2921, a novel TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

医学 抗体-药物偶联物 结合 抗体 实体瘤 药品 癌症研究 单克隆抗体 癌症 内科学 药理学 免疫学 数学分析 数学
作者
Shuiping Gao,Jian Chen,Congxiao Lu,XingYa Li,Xiaobo Du,Yu-Meng Ji,Dan Li,Liuzhong Yang,Jian Zhang,Peipei Wang,Hanqi Zhao,Fan Gao,Shuhai Wang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 3029-3029 被引量:1
标识
DOI:10.1200/jco.2025.43.16_suppl.3029
摘要

3029 Background: TROP-2 (trophoblast cell surface antigen 2) is commonly overexpressed in multiple solid tumors and associated with poor prognosis. 9MW2921 is a novel TROP-2 ADC developed with a site-specific linker to conjugate the class of novel camptothecin-based payload Mtoxin, with a drug-to-antibody-ratio (DAR) of 4. Here we report the safety and efficacy data of 9MW2921 in patients with advanced solid tumors in a phase 1 study. Methods: 9MW2921 was administered by intravenous infusion at doses of 1.0-6.0 mg/kg once every 3 weeks. Primary objectives were assessment of dose-limiting toxicity, safety and the recommended phase 2 dose/maximum dose. Results: As of 12 November, 2024, thirty-nine patients (pts) were enrolled and treated at dose levels of 1.0 (N = 1), 2.0 (N = 3), 2.5 (N = 12), 3.0 (N = 20) and 4.5 (N = 3) mg/kg. The average age of all patients was 55.6 (range: 37-72) years with 20.5% male and 79.5% female. The median prior therapy lines were 2 (range: 1~11); 48.7% pts treated after immunotherapy. Three patients at 4.5mg/kg experienced at least one dose limiting toxicity (DLT), and this dose level was considered intolerable. No other pts was observed DLTs at the 1.0~3.0 mg/kg groups. The most common ≥grade 3 (≥5% pts)TRAEs were stomatitis, anemia, white blood cell (WBC) count decreased, neutropenia, lymphocyte count decreased, rash, vomiting and platelet count decreased. There were no TRAEs leading to death. 38 pts were evaluable for efficacy with at least one post-baseline tumor assessment, 12 pts achieved partial response and 16 pts maintained stable disease. The ORR of 3.0 mg/kg was 42.1% (8/19) and DCR was 84.2% (16/19). The ORR, DCR of 3.0 mg/kg in patients diagnosed with endometrial cancer (4 pts), HR+/HER2- breast cancer (4 pts), HER2- gastric cancer (4 pts) and Non-squamous non-small cell lung cancer (4 pts) were 75%, 100%; 50%, 75%; 50%, 100%; 25%, 100%, respectively. Conclusions: The data indicated that 9MW2921 has acceptable tolerability and promising anti-tumor activity in patients with advanced EC, HR+/HER2- BC, HER2- GC and nsq-NSCLC. Clinical trial information: NCT05990452 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yy完成签到 ,获得积分10
刚刚
娜子发布了新的文献求助10
刚刚
白羽清风兮完成签到,获得积分10
刚刚
Gmj发布了新的文献求助10
1秒前
懵懂的飞飞完成签到,获得积分10
1秒前
1秒前
2秒前
ding的应助被李恒采纳,获得10
2秒前
wl完成签到,获得积分10
2秒前
平常的傲旋完成签到 ,获得积分10
3秒前
哈哈哈完成签到,获得积分10
4秒前
Eric发布了新的文献求助10
4秒前
zchhh完成签到 ,获得积分10
5秒前
花样年华发布了新的文献求助10
5秒前
隋玉发布了新的文献求助10
5秒前
5秒前
谨慎枫叶发布了新的文献求助10
6秒前
7秒前
神宝嘎li发布了新的文献求助10
7秒前
英俊的铭的应助被小王采纳,获得10
7秒前
孝择发布了新的文献求助10
7秒前
海边捡贝壳完成签到 ,获得积分10
7秒前
科研小郭发布了新的文献求助30
7秒前
星辰大海的应助被15采纳,获得30
8秒前
搜集达人的应助被大气的嚓茶采纳,获得10
8秒前
体贴鹰发布了新的文献求助10
8秒前
仙八完成签到 ,获得积分10
8秒前
田様的应助被钟梓袄采纳,获得10
9秒前
CipherSage的应助被钟梓袄采纳,获得10
9秒前
hitech的应助被小橘子采纳,获得20
9秒前
爆米花的应助被钟梓袄采纳,获得10
9秒前
Crssss的应助被单纯乘风采纳,获得10
9秒前
9秒前
pp发布了新的文献求助10
10秒前
美羊羊羊完成签到,获得积分10
10秒前
10秒前
11秒前
11秒前
12秒前
冬瓜鑫发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183091
求助须知:如何正确求助?哪些是违规求助? 9572406
关于积分的说明 21825003
捐赠科研通 7779812
什么是DOI,文献DOI怎么找? 3433837
关于科研通互助平台的介绍 2558045
邀请新用户注册赠送积分活动 2480046